Vol. 37 No. 3 (2020): June
Antimicrobial

Plasmatic concentracion of piperacillin/tazobactam in pediatric patients on ECMO support. Preliminary analysis

PDF (Español (España))
  • Brenda Lara Zylbersztajn,
  • Giannina Izquierdo Copiz,
  • Daniel Navea Montoya,
  • Juan Pablo Torres Torreti,
  • Cristian Valverde Goñi
Brenda Lara Zylbersztajn
Clinica Las Condes
Giannina Izquierdo Copiz
Clínica Las Condes
Daniel Navea Montoya
Clínica Las Condes
Juan Pablo Torres Torreti
Clínica Las Condes
Cristian Valverde Goñi
Clínica Las Condes

Published 2020-07-02

Keywords

How to Cite

1.
Zylbersztajn BL, Izquierdo Copiz G, Navea Montoya D, Torres Torreti JP, Valverde Goñi C. Plasmatic concentracion of piperacillin/tazobactam in pediatric patients on ECMO support. Preliminary analysis. Rev. Chilena. Infectol. [Internet]. 2020 Jul. 2 [cited 2025 Nov. 4];37(3). Available from: https://revinf.cl/index.php/revinf/article/view/598

Copyright (c) 2020 Brenda Lara Zylbersztajn, Giannina Izquierdo Copiz, Daniel Navea Montoya, Juan Pablo Torres Torreti, Cristian Valverde Goñi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Background: Pharmacokinetics and optimal dosing of piperacillin tazobactam (PT) have not been well studied in pediatric patients undergoing extracorporeal oxygenation membrane (ECMO). Aim: To describe piperacillin plasmatic concentration and evaluate achievement of pharmaccokinetic/pharmacodinamic objective in patients on ECMO support. Method: We report three pediatric patients admitted to the Pediatric Intensive Care Unit, treated with PT undergoing ECMO. Plasmatic concentrations of piperacillin were obtained in the middle of the dosing interval using high performance liquid chromatography. Results: Plasmatic concentrations were 51,7-14,1 and 6,5 μg/mL for patient A, B and C respectively. Only one patient reached adequate concentrations. Conclusion: These preliminary results suggest that availability of plasmatic concentrations of piperacillin could optimize the achievement of pharmacokinetic/pharmacodynamic objectives in pediatric patients on ECMO support.Background: Pharmacokinetics and optimal dosing of piperacillin tazobactam (PT) have not been well studied in pediatric patients undergoing extracorporeal oxygenation membrane (ECMO). Aim: To describe piperacillin plasmatic concentration and evaluate achievement of pharmaccokinetic/pharmacodinamic objective in patients on ECMO support. Method: We report three pediatric patients admitted to the Pediatric Intensive Care Unit, treated with PT undergoing ECMO. Plasmatic concentrations of piperacillin were obtained in the middle of the dosing interval using high performance liquid chromatography. Results: Plasmatic concentrations were 51,7-14,1 and 6,5 μg/mL for patient A, B and C respectively. Only one patient reached adequate concentrations. Conclusion: These preliminary results suggest that availability of plasmatic concentrations of piperacillin could optimize the achievement of pharmacokinetic/pharmacodynamic objectives in pediatric patients on ECMO support.
PDF (Español (España))